YahooOctober 26, 2026 at 10:41 AM NY15 Days Ago
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
